Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer

An, Young‐Sil; Yoon, Joon-Kee; Lee, Su Jin; Song, Hee-Sung; Yoon, Seok-Ho; Jo, Kyung-Sook

doi:10.1007/s12149-013-0697-5

Cited by 35 publications

(29 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be explained by the relative radiosensitivity of the serous cells in the parotid glands. However, the mucinous tissue of the submandibular glands might have contributed to a radioprotective effect [13,16].…”

Section: Discussionmentioning

confidence: 99%

Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up

Feng²,

Ouyang³

et al. 2015

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up

Feng²,

Ouyang³

et al. 2015

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…Swelling and pain of salivary gland are the most common symptoms in early sialadenitis while xerostomia is the most prominent symptom in chromic sialadenitis after RAI therapy. An YS et al [5] found the ratio of late-phase (mean 338 days) symptomatic sialadenitis as 10% after RAI therapy. Early sialadenitis occurs in a short time after RAI theraphy with swelling and pain symptoms and usual-ly subsides over a few days spontane-ously.…”

Section: Discussionmentioning

confidence: 99%

“…Parotid gland involve-ment is observed more frequently as it contains more serous cells than mucous cells [7]. Moreover, high mucin secre-tion in the submandibular glands pro-tect these glands from exposure to radi-ation [5]. Interestingly, although its rea-son has not been fully explained yet, there are studies reporting that the right parotid gland is affected more [5].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, high mucin secre-tion in the submandibular glands pro-tect these glands from exposure to radi-ation [5]. Interestingly, although its rea-son has not been fully explained yet, there are studies reporting that the right parotid gland is affected more [5]. Moreover, Jeong et al [8] found that xerostomia is most frequently associat-ed with submandibular gland dysfunc-tion.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Development of parotitis after radioiodine therapy in a differentiated thyroid cancer patient: Case report

Hasbek

Durmuş²,

Engin

et al. 2016

Cumhuriyet Med J

View full text Add to dashboard Cite

SUMMARYIn this article, we report a 51 years old female patient treated with radioactive iodine (RAI-131 I) treatment for thyroid papillary carcinoma and developing parotitis on the 24 hour following treatment. Siaload enitis after high dose ablative therapy with 131 I is a relatively common complication with a low clinical impression. Taste alteration or loss, and nausea and vomiting due to radiation sickness are the other most frequent side effects. Xerostomia is an important problem increasing morbidity of the patients. For this reason, it is important to prevent xerostamia by following serum amylase levels in symptomatic patients. By taking into account that not only bacterial and viral factors but also radiation may cause sialoadenitis, one has to rule out other parotisis possibilities by clinical and laboratory findings before claiming that salivary gland enlargement developing after radioiodine is a complication of radiation. Moreover, history of RAI treatment should be given importance in patients applying either to emergency services or to Ear Nose Throat and Infectious Diseases Department with dry mouth.Keywords: Radioiodine therapy, differentiated thyroid carcinoma, parotitis ÖZET Bu makalede, diferansiye tiroid papiller karsinom nedeniyle radyoaktif iyot (RAI-131 I) tedavisi verilen ve tedavinin 24. saatinde parotitis gelişen 51 yaşındaki kadın hastayı sunduk. 131 I ile yüksek doz ablasyon tedavi sonrası siyaloadenit, düşük klinik izlem ile birlikte rölatif olarak sık bir komplikasyondur. Radyasyon hastalığı nedeniyle tat alma bozukluğu veya kaybı, ve bulantı ve kusma diğer en sık yan etkilerdir. Kserostomi hastaların morbiditesini artıran önemli bir problemdir. Bu nedenle, semptomatik hastalarda serum amilaz d üzeylerinin takibi, kserostominin önlenmesi için önemlidir. Bakteriyel ve viral etkenler dışında radyasyonun da sialadenit yapabileceği dikkate alınarak, radyoaktif iyot sonrası gelişen tükürük bezi büyümesinin, radyasyon komplikasyonu olduğunu söylemeden önce, klinik ve laboratuvar bulgularla birlikte diğer parotit olasılıklarının da ekarte edilmesi gereklidir. Bunun yanısıra, gerek acil servislerde gerekse Kulak Burun Boğaz (KBB) departmanlarında ağız kuruluğu ile başvuran hastalarda, hikayede mutlaka RAI tedavi öyküsünün de sorgulanması önemlidir.Anahtar sözcükler: Radyoiyot tedavi, diferansiye tiroid karsinom, parotit 54

show abstract

“…Intravenously administered 99m Tc-pertechnetate gradually accumulates in the salivary glands over 20 min postadministration and is then excreted as saliva production is enhanced. This type of scintigraphy yields semiquantitative data on uptake ratios and %excretion values [16][17][18]. However, no reliable method has yet been developed to predict functional impairment of salivary glands at the time of 131 I ablation therapy.…”

Section: Introductionmentioning

confidence: 99%

Significance of Salivary Gland Radioiodine Retention on Post-ablation 131I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma

Lee

et al. 2014

Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Purpose We investigated whether 131 I whole-body scintigraphy could predict functional changes in salivary glands after radioiodine therapy. Methods We evaluated 90 patients who received initial highdose (≥3.7 GBq) radioiodine therapy after total thyroidectomy. All patients underwent diagnostic (DWS) and postablation (TWS) 131 I whole-body scintigraphy. Visual assessment of salivary radioiodine retention on DWS and TWS was used to divide the patients into two types of groups: a DWS+ or DWS-group and a TWS+ or TWS-group. Salivary gland scintigraphy was also performed before DWS and at the first follow-up visit. Peak uptake and %washout were calculated in ROIs of each gland. Functional changes (Δuptake or Δwashout) of salivary glands after radioiodine therapy were compared between the two groups. Results Both peak uptake and the %washout of the parotid glands were significantly lower after radioiodine therapy (all p values <0.001), whereas only the %washout were significantly reduced in the submandibular glands (all p values <0.05). For the parotid glands, the TWS+ group showed larger Δuptake and Δwashout after radioiodine therapy than did the TWS-group (all p values <0.01). In contrast, the Δuptake and Δwashout of the submandibular glands did not significantly differ between the TWS+ and TWS-groups (all p values >0.05). Likewise, no differences in Δuptake or Δwashout were apparent between the DWS+ and DWS-groups in either the parotid or submandibular glands (all p values >0.05). Conclusion Salivary gland radioiodine retention on postablation 131 I scintigraphy is a good predictor of functional impairment of the parotid glands after high-dose radioiodine therapy.

show abstract

Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer

Abstract: Symptomatic late-onset sialadenitis occurred at an incidence of 10.2 %, and salivary gland function was affected in both parotids in most patients.

Cited by 35 publications

References 16 publications

Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up

Systematic evaluation of salivary gland damage following I-131 therapy in differentiated thyroid cancer patients by quantitative scintigraphy and clinical follow-up

Development of parotitis after radioiodine therapy in a differentiated thyroid cancer patient: Case report

Significance of Salivary Gland Radioiodine Retention on Post-ablation 131I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma

Contact Info

Product

Resources

About